Investors
OMX Stockholm
( %)
HNSA SEK
Some content on this page is only available in English. All material required under applicable law, regulation or code is available in English and Swedish.
Press releases
Our latest press releases
Hansa Biopharma to participate in Virtual US Bancorp / BTIG Kidney Health Forum
13/10/2026
Hansa Biopharma to participate in 26th Annual Biotech in Europe Forum
02/10/2026
Hansa Biopharma Partners with Cradle to Advance AI-Driven Protein Design and Engineering
01/10/2026
Hansa Biopharma Announces New Board Appointments
Regulatory press release
24/09/2026
Hansa Biopharma in brief
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions.
